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Currently, imatinib and dasatinib are the only tyrosine-kinase inhibitors approved in the US and Europe for the treatment of blast
crisis of chronic myeloid leukemia (BC-CML) at diagnosis, while ponatinib is the only inhibitor used in patients bearing T315I
mutation. Here we report the case of a 61-year-old man diagnosed with B-cell lymphoid BC-CML, initially treated with imatinib
800mg day and then with dasatinib 140mg day because of intolerance. A complete cytogenetic response (CCyR) was achieved at
three months; however, three months later a relapse was observed, and the T315I mutation was detected. Ponatinib 45mg once
daily was then started together with a short course of chemotherapy. Bone marrow evaluation after six months of therapy showed
the regaining of CCyR, together with the achievement of a deep molecular response. However, one year from ponatinib start the
patient experienced a new disease relapse; he was effectively treated with ponatinib and chemotherapy once again, but in the
meanwhile an ischemic stroke was detected. This case report confirms the high efficacy of ponatinib monotherapy in BC-CML
patients, representing a valid option for non-allogeneic stem cells transplantation eligible cases and the only one available for those
carrying the T315I mutation.
1. Introduction
Chronic myeloid leukemia (CML) prognosis changed dra-
matically with the development of tyrosine-kinase inhibitors
(TKIs) that potently interfere with the interaction between
the BCR-ABL1 protein and adenosine triphosphate (ATP),
thus blocking proliferation of themalignant cellular clone [1].
This targeted approach has markedly increased survival of
CMLpatients and greatly reduced the frequency of blast crisis
(BC) compared to the pre-TKI era. In fact, the incidence of
BC now ranges between 0.7 and 4.5%, showing the highest
incidence in the first year after diagnosis and then decreasing
[2, 3].
A percentage of patients between 0.9 and 6.7% are al-
ready in BC at diagnosis [2–5]. More recently, in the EUTOS
population-based registry, the incidence of BC at diagnosis
was found to be about 2.2% [3]. Median survival ranges
between 6 and 11.8 months [6].
According to the European LeukemiaNet (ELN) recom-
mendations, BC is defined using the threshold blast count in
the peripheral blood or bone marrow at 30% [7].
Up to 80% of all BC patients show additional chro-
mosomal aberrations (ACA) [8], and at least 77% carry
mutations in the ABL1 domain. Therefore, their mutational
status should also be evaluated, since it is associated with
different prognoses, for example, T315I mutation-positive
cases compared to others [9–11].
At diagnosis, treatmentmainly depends on the type of BC
(myeloid versus lymphoid), mutational status, and previous
therapies. Treatment optionsmay include TKIs, conventional
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Figure 1: Bone marrow aspirate morphology at diagnosis, showing atypical granular lymphoblasts.
chemotherapy, allogeneic stem cells transplantation (HSCT),
and/or other treatment modalities. To date, imatinib and
dasatinib are the onlyTKIs approved in theUS andEurope for
treatment of BC at diagnosis, while ponatinib is the only one
which can be used also in patients harboring T315I mutation
[12–16].
Here we report the case of a 61-year-old man diagnosed
with B-cell lymphoid BC-CML initially treated with imatinib,
which was soon suspended because of intolerance, followed
by dasatinib.Then, he acquired a T315Imutation but achieved
a deep molecular response (MR4) on ponatinib therapy.
Furthermore, ponatinib monotherapy was able to maintain
this patient in CML-chronic phase for about one year before
he died because of an infective complication.
2. Case Presentation
In January 2015, a 61-year-old man was referred to our hos-
pital because of asthenia, diffuse bone pain, fever, and cuta-
neous hemorrhagic diathesis. Laboratory tests showed amild
anemia (hemoglobin, 12 g/dL), leukocytosis (white blood
cells count, 22 × 109/L, with neutrophils 57%; lymphocytes
11%;monocytes 2%; eosinophils 6%; basophils 1%;myelocytes
6%; metamyelocytes 4%; blast cells 13%), and severe throm-
bocytopenia (platelet count, 4 × 109/L).The patient was obese
and suffered from chronic bronchitis; in addition, he was an
active smoker (about 40 cigarettes per day) and an alcohol
abuser, with three previous episodes of suicide attempt.
Bone marrow morphological analysis showed an atypical
granular lymphoblastic infiltration of 70% (Figure 1), which
was confirmed by flow cytometry immunophenotyping
(high positivity for CD10/CD19/CD34/CD99/CD79a/TdT;
weak positivity for CD33 (60%)/CD38 (80%); negativity for
CD3/CD13/CD14/CD20/CD117/MPO). Cytogenetic study of
20 metaphases revealed a typical 46, XY, t(9;22)(q34;q11.2)
translocation, and qualitative polymerase chain reaction
(PCR) demonstrated the presence of the BCR-ABL1 fusion
transcript, with a typical e13a2 configuration. Baseline assess-
ment of BCR-ABL1mutational status with Sanger sequencing
was negative, datum which was also retrospectively con-
firmed by ultradeep sequencing. Therefore, a diagnosis of B-
cell lymphoid BC of CML was made. As a matched sibling
donor was not available and the patient categorically refused
HSCT, we decided not to start a search for a matched unre-
lated donor. Because of a previous exposition to hepatitis B
virus, a prophylactic treatment with lamivudinewas initiated.
The patient was initially treated with imatinib 800mg
day, which was suspended approximately after one month
because of intolerance (grade III crippling cramps, periorbital
edema, and conjunctival hemorrhage), and then he started
dasatinib 140mg day. At the same time, methylprednisolone
was administered at a full dose and then decreased for the
appearance of diabetes which required treatment with oral
hypoglycemic drugs and then also with insulin.
Hematological response was obtained after one month,
and at three months bone marrow evaluation showed a
complete cytogenetic response (CCyR), together with a BCR-
ABL1 transcript level of 0.2% according to the International
Scale (IS).
Nevertheless, three months later a BC-CML relapse was
observed, with a BCR-ABL1 transcript level of 89.5% accord-
ing to IS, and a new evaluation of BCR-ABL1 mutational
status revealed the presence of T315I mutation. Cytological
and flow cytometric analyses of cerebrospinal fluid showed
no leukemic cells.
As suggested by ELN 2013 recommendations, ponatinib
45mg once daily was started together with chemotherapy
(vincristine intravenously every seven days for three cycles
and oral prednisone). Due to patient’s comorbidities, an
antiplatelet therapy with ASA 100mg day was coprescribed
in order to reduce the risk of arterial thrombotic events.
After three months of ponatinib therapy, bone marrow
evaluation showed the regaining of a CCyR and a BCR-ABL1
transcript of less than 10% according to IS.
The drug was fairly well tolerated, even though after two
months severe upper abdominal burning pain irradiating to
the back appeared. Blood analysis showed an increase in
lipase and amylase levels (grade III pancreatic toxicity), and
an abdomen CT scan showed a mild pancreatitis. It was then
decided to maintain ponatinib at the same dosage and to
strictly monitor the patient, achieving then a spontaneous
resolution of all symptoms.
Bone marrow evaluation after six months of therapy
confirmed CCyR, together with the achievement of a deep
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Figure 2: BCR-ABL1 transcript level during TKIs therapy.
molecular response, with a BCR-ABL1 transcript level of
0.004% according to IS (MR4) (Figure 2).
Nevertheless, after about one year from ponatinib start,
the patient experienced disease relapse: bone marrow mor-
phological analysis showed an atypical granular lymphoblas-
tic infiltration of 55%, which was confirmed by flow cytom-
etry immunophenotyping (high positivity for CD10/CD19/
CD79a/CD99/TdT; weak positivity for CD33 (30%)/CD38
(50%); negativity forCD20/CD34). In addition, a new cytoge-
netic abnormality was detected, his karyotype being the fol-
lowing: 46,XY,t(9;22)(q34,q11.2) [3]/47,XY,t(9;22)(q34;q11.2),
+der(1;19)(p11;q11) [4].
Due to the good response to the previous chemotherapy,
a new course of intravenous vincristine and oral prednisone
was started. However, after the second cycle of chemotherapy,
the patient showed dysarthria and weakness of the right leg;
therefore he was hospitalized to clarify the origin of these
new neurological symptoms.With the hypothesis of a central
nervous system (CNS) localisation of lymphoid BC-CML, a
new cytological and flow cytometric analysis of cerebrospinal
fluid was performed but it showed no leukemic cells; on the
contrary, a CNS CT scan demonstrated an ischemic stroke
with numerous recent lesions in the periventricular area
and within the frontal-parietal cortex of the left hemisphere.
Accordingly, due to the vascular etiology of the ischemic
event, anticoagulant therapy with low molecular weight
heparin (LMWH) was added to ASA, and statins and antihy-
pertensive therapies were started. Meanwhile, ponatinib and
intravenous vincristine were regularly administered, leading
to the rapid achievement of a complete normalisation of
blood cells count with no need of red blood cells or platelets
transfusion.
Approximately after twomonths fromhospitalization, the
patient developed a septic shock due to a pulmonary infection
not responsive to empiric antibiotic therapy and died.
3. Discussion
Even if TKIs have completely changed the outcome and
survival of CML patients, treatment of advanced phases still
remains a clinical challenge, particularly for patients not
eligible to HSCT, which remains to date the only potentially
curative strategy for eligible patients.
In the case reported here, the patient was not eligible to
HSCT due to his comorbidities correlated with a Sorror score
of 8, identifying a 2-year non-relapse mortality of 41% and a
2-year overall survival of 34% [17].
In addition, due to the complexity of psychological
characteristics of the patient who refused not only HSCT
but also hospitalization, he was initially treated with TKI
monotherapy. As reported in the literature, hematologic and
cytogenetic responses with single agent TKIs are achieved in
about 50 and 12% of the cases, respectively, with the 12-month
overall response ranging between 25 and 49% and themedian
survival between 6 and 11.8months [6].Outcomeof lymphoid
BC-CML treatedwith dasatinib varies between 39 and 80% of
hematologic remission and from40 to 90%of any cytogenetic
response [6, 18, 19]. Concerning molecular response, no data
have been reported in the literature so far. Of note, in a ret-
rospective analysis aimed at characterizing mutation devel-
opment in patients with newly diagnosed CML treated with
imatinib or dasatinib frontline, a narrower spectrumofmuta-
tions in dasatinib-treated patients was found, with the occur-
rence of T315I mutation in approximately 17% of cases [20].
Indeed, our patient experienced disease relapse within six
months of dasatinib treatment with the occurrence of T315I
mutation.
Since the patient was in BC at the time of diagnosis, he
was investigated for BCR-ABL1 mutational status by Sanger
sequencing and found negative. However, Soverini et al. [21]
and Baer et al. [22] reported that the T315I mutation can
be identified by means of ultradeep sequencing approxi-
mately three months before the Sanger sequencing detection
threshold is reached. Therefore, the same specimen was
retrospectively analyzed by ultradeep sequencing, but despite
a sequencing depth of 7614 reads (theoretically enabling a
sensitivity of approximately 0.03%) no T315I mutation was
detected. Interestingly, in 4% of all alleles, a 35 bp insertion,
already reported in the literature as “35INS,” was identified.
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The contribution of this insertion to TKI resistance is still
a matter of debate. However, a recent functional in vitro
study has indicated that the BCR-ABL1 35INS isoform is not
a functional kinase, thus it should not have any role in
sustaining the disease and triggering drug resistance [23].
Due to the low incidence of BC-CML, studies on the
combination of TKIs with chemotherapy are rather scanty
and usually with a limited number of enrolled patients.
Considering that patients with lymphoid BC can be treated
with acute lymphoblastic leukemia- (ALL-) type induction
regimens, with our patient being not eligible to HSCT, we
decided to administer three courses of vincristine and high
dose corticosteroids in association with ponatinib. Since
only ponatinib shows activity also against T315I mutation,
it was administered at full dose in our patient, despite its
potential side effect profile. As reported in phase 2 PACE
study of ponatinib in Ph+ leukemias, the median time to
a major hematologic response in BC-CML patients was
4.1 weeks (range, 1.7 to 16.1), and the estimated rate of a
sustained response at 12 months was 42%. Overall survival
was estimated to be 29%at 12months (median, 7months), but
no data were reported about achievement of major molecular
response (MMR) [16].
Response to treatment is the most important prognostic
factor for survival in BC-CML patients [24, 25]. In particular,
best results are obtained in patients returning to chronic
phase especially if cytogenetic or molecular responses are
achieved.
Concerning ponatinib safety profile, arterial thrombotic
events are reported in about 22% of all treated patients,
showing a linear correlation with the drug dosage [16]. It
has to be considered that our patient bears different cardio-
vascular risk factors, including hypertension, hypercholes-
terolemia, steroid-induced diabetes, alcohol abuse, smoking
habit, and obesity; however, ponatinib at a dosage of 45mg
day represented the only possible therapeutic option for such
a complex subject.
Our data confirm the high efficacy of ponatinib in BC-
CML patients and the potent activity of this drug also in
achieving molecular response in such patients and maintain-
ing the chronic phase of the disease for almost one year. In
addition, another significant aspect in this case is represented
by the good quality of life for the patient, who remained an
outpatient for the entire treatment duration.
In conclusion, ponatinib monotherapy or in association
with chemotherapy is a valid treatment option for non-HSCT
eligible BC-CML patients and the only one available for
those carrying the T315I mutation, which can develop during
dasatinib therapy frequently.
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